Cboe Global Markets (CBOE)
BATSFinancialsFinancial - Data & Stock ExchangesSnapshot 2026-11-04
$345.21+0.27%
Close 2026-11-04 · 1-day change
BATSFinancialsFinancial - Data & Stock ExchangesSnapshot 2026-11-04
Research Workspace
Put CBOE beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Financials is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
The reason to own it still holds.
View ThesisRevenue growth is slowing — up about 14% over the past year and decelerating.
View GrowthRanks in the weakest quality tier of its industry — roughly the bottom 43%, softest on free-cash-flow margins.
View QualityMiddle-of-the-pack management execution.
View ManagementExpectations look high — what the market is pricing in runs ahead of what analysts forecast.
View ValuationThis stock is volatile — it swings about 2% on a typical day and fell roughly 37% in its worst 12-month stretch.
View RiskCBOE's organic revenue growth must keep compounding to justify the price. Revenue grew 18% year over year in the latest quarter. The company beat its earnings estimate by 6.1%. It trades at 25 times earnings versus a 12 times peer median. The market is pricing in more growth than we forecast. A guidance cut would hit the stock disproportionately hard. Peer multiples imply a price about 31% below where it trades. Our read remains intact. This read is provisional.
Trailing returns as of 2026-11-04. CBOE is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 18 analysts currently covering CBOE (as of Nov 2026).
Based on 5 Wall Street analysts offering 12-month price targets for CBOE in the last 4 months.
Continue this research
Compare CBOE with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| CBOE Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 9 valuation methods, at three horizons. As of 2026-11-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Financial Exchanges & Data — fair value, gap to price, and forward P/E.
Compare the value case
Put CBOE next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Grow organic total net revenue
Official transcript confirms organic revenue growth objectives.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-11-04. EPS is implied from price ÷ P/E. Not investment advice.
Current $345.21
The last 12 months of price, then the range of analyst 12-month targets from today’s $345.21.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Top 10% on quality vs scored peers
A second lens on the 12-month fair value: for companies that score high on measured quality (profitability, balance-sheet safety, earnings stability), this read trusts more of today's profit margins instead of averaging them toward their multi-year history the way the headline number does. Shown alongside the fair value above, not in place of it. A diagnostic, not a price target or a buy/sell signal.
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Advances: Grow organic total net revenue
EPS and revenue beat confirms strong organic growth execution.
Advances: Expand products and clearing services
Expanding trading hours directly advances product expansion objective.
Advances: Control adjusted operating expenses
Dividend increase signals confidence in cost control and cash flow.
Threatens: Strategic realignment for core business focus
Repositioning may divert focus from core business strategy.
Advances: Strategic realignment for core business focus
Expanding options hours aligns with strategic realignment goals.
Advances: Expand products and clearing services
Launch of new products supports diversification and growth goals.
Advances: Strategic realignment for core business focus
Launch aligns with strategic realignment for core business focus.